---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-097468"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:52:51.886007+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q3 revenue $21.3M (+30% YoY); GAAP net loss $(9.1)M; guides FY24 rev $88-$92M

## Summary
- Q3 revenue $21.3M, up 30% YoY from $16.3M; gross profit $13.4M (+37%); margin 63%.
- GAAP net loss $(9.1)M ($(0.50)/share) vs $(2.9)M loss last year; non-GAAP net income $2.3M ($0.12/sh) vs $1.6M.
- Adjusted EBITDA $2.7M, up from $0.9M; cash and equivalents $16.1M; paid down $2M on term loan post-quarter.
- Updated FY2024 guidance: revenue $88-$92M, Adjusted EBITDA $8-$10M; won 5 DAAP deals in Q3.
- Net revenue retention 127% (rolling 12-month); top-20 pharma customers revenue per avg $2.8M vs $1.9M.

## SEC filing metadata
- accession: 0001213900-24-097468
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024097468/0001213900-24-097468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024097468/ea0221012-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-097468
- JSON: https://secwatch.observer/filing/0001213900-24-097468.json
- Plain text: https://secwatch.observer/filing/0001213900-24-097468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.